As of May 29
| +0.57 / +2.96%|
The 9 analysts offering 12-month price forecasts for Momenta Pharmaceuticals Inc have a median target of 20.00, with a high estimate of 27.00 and a low estimate of 7.00. The median estimate represents a +0.76% increase from the last price of 19.85.
The current consensus among 9 polled investment analysts is to Buy stock in Momenta Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.